A2bR checkpoint inhibitor (Vernalis/Corvus Pharmaceuticals)

N/A

Report date: 2025/06/11 10:25:50
NME

Base Information

Drug NameA2bR checkpoint inhibitor (Vernalis/Corvus Pharmaceuticals)
Drug Alias Nameadenosine A2B receptor antagonists (Corvus)checkpoint inhibitor B (Corvus Pharmaceuticals)
ClassificationSmall molecules
Mechanisms of ActionAdenosine A2b receptor antagonistsImmunostimulantsT lymphocytes stimulants
TargetsAdenosine A2b receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesCorvus Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A